Current portfolio

Aelin Therapeutics

Novel therapeutic modality to induce functional knockdown of a target protein

  • Sector
    Healthcare
  • Country
    Belgium
  • Fund
    LSP HEF 2,LSP 5
  • Entry
    2017
  • Web
Logo

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180